Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) | Acute Coronary Syndromes | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.205.38.159. Please contact the publisher to request reinstatement.
1.
Hall  WDClark  LTWenger  NK  et al. African-American Lipid and Cardiovascular Council, The metabolic syndrome in African Americans: a review.  Ethn Dis 2003;13 (4) 414- 428PubMedGoogle Scholar
2.
Grundy  SMBrewer  HB  JrCleeman  JISmith  SC  JrLenfant  CAmerican Heart Association; National Heart, Lung, and Blood Institute, Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition.  Circulation 2004;109 (3) 433- 438PubMedGoogle ScholarCrossref
3.
Eckel  RHKahn  RRobertson  RMRizza  RA Preventing cardiovascular disease and diabetes: a call to action from the American Diabetes Association and the American Heart Association.  Circulation 2006;113 (25) 2943- 2946PubMedGoogle ScholarCrossref
4.
Mykkänen  LKuusisto  JPyörälä  KLaakso  MHaffner  SM Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects.  J Hypertens 1994;12 (12) 1425- 1432PubMedGoogle Scholar
5.
Giles  TDSander  GE Pathophysiologic, diagnostic, and therapeutic aspects of the metabolic syndrome.  J Clin Hypertens (Greenwich) 2005;7 (11) 669- 678PubMedGoogle ScholarCrossref
6.
Mancia  G The association of hypertension and diabetes: prevalence, cardiovascular risk and protection by blood pressure reduction.  Acta Diabetol 2005;42 ((suppl 1)) S17- S25PubMedGoogle ScholarCrossref
7.
Wagh  AStone  NJ Treatment of metabolic syndrome.  Expert Rev Cardiovasc Ther 2004;2 (2) 213- 228PubMedGoogle ScholarCrossref
8.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.  JAMA 2002;288 (23) 2981- 2997[published corrections appear in JAMA. 2003;289(2):178 and JAMA. 2004;291(18):2196]PubMedGoogle ScholarCrossref
9.
Wright  JT  JrDunn  JKCutler  JA  et al. ALLHAT Collaborative Research Group, Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.  JAMA 2005;293 (13) 1595- 1608PubMedGoogle ScholarCrossref
10.
Rahman  MPressel  SDavis  BR  et al.  Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Arch Intern Med 2005;165 (8) 936- 946PubMedGoogle ScholarCrossref
11.
Rahman  MPressel  SDavis  BR  et al. ALLHAT Collaborative Research Group, Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate.  Ann Intern Med 2006;144 (3) 172- 180PubMedGoogle ScholarCrossref
12.
Davis  BRCutler  JAGordon  DJ  et al. ALLHAT Research Group, Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Am J Hypertens 1996;9 (4, pt 1) 342- 360PubMedGoogle ScholarCrossref
13.
Zhu  SWang  ZHeshka  SHeo  MFaith  MSHeymsfield  SB Waist circumference and obesity-associated risk factors among whites in the Third National Health and Nutrition Examination Survey: clinical action thresholds.  Am J Clin Nutr 2002;76 (4) 743- 749PubMedGoogle Scholar
14.
Pyörälä  KBallantyne  CMGumbiner  B  et al. Scandinavian Simvastatin Survival Study (4S), Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S).  Diabetes Care 2004;27 (7) 1735- 1740PubMedGoogle ScholarCrossref
15.
Alberti  KGZimmet  PShaw  J Metabolic syndrome—a new world-wide definition: a consensus statement from the International Diabetes Federation.  Diabet Med 2006;23 (5) 469- 480PubMedGoogle ScholarCrossref
16.
Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group, Diuretic versus α-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Hypertension 2003;42 (3) 239- 246PubMedGoogle ScholarCrossref
17.
Whelton  PKBarzilay  JCushman  WC  et al. ALLHAT Collaborative Research Group, Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Arch Intern Med 2005;165 (12) 1401- 1409PubMedGoogle ScholarCrossref
18.
SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP).  JAMA 1991;265 (24) 3255- 3264PubMedGoogle ScholarCrossref
19.
Kostis  JBWilson  ACFreudenberger  RSCosgrove  NMPressel  SLDavis  BRSHEP Collaborative Research Group, Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes.  Am J Cardiol 2005;95 (1) 29- 35PubMedGoogle ScholarCrossref
20.
Black  HRElliott  WJGrandits  G  et al. CONVINCE Research Group, Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.  JAMA 2003;289 (16) 2073- 2082PubMedGoogle ScholarCrossref
21.
Hansson  LLindholm  LHEkbom  T  et al.  Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity: the Swedish Trial in Old Patients With Hypertension-2 Study.  Lancet 1999;354 (9192) 1751- 1756PubMedGoogle ScholarCrossref
22.
Brown  MJPalmer  CRCastaigne  A  et al.  Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).  Lancet 2000;356 (9227) 366- 372[published correction appears in Lancet. 2000;356(9228):514]PubMedGoogle ScholarCrossref
23.
Turnbull  F Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials.  Lancet 2003;362 (9395) 1527- 1535PubMedGoogle ScholarCrossref
24.
Turnbull  FNeal  BAlgert  C  et al. Blood Pressure Lowering Treatment Trialists' Collaboration, Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials.  Arch Intern Med 2005;165 (12) 1410- 1419PubMedGoogle ScholarCrossref
25.
Black  HRDavis  BRBarzilay  J  et al.  Metabolic and clinical outcomes in non-diabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the ALLHAT study [published online ahead of print November 13, 2007].  Diabetes Care In pressPubMedGoogle Scholar
26.
Weber  MA Hypertension, the metabolic syndrome, and the risk of developing diabetes: is it time to change the guidelines?  J Clin Hypertens (Greenwich) 2004;6 (8) 425- 427PubMedGoogle ScholarCrossref
27.
Messerli  FHWeber  MA Long-term cardiovascular consequences of diuretics vs calcium channel blockers vs angiotensin-converting enzyme inhibitors.  JAMA 2003;289 (16) 2067- 2068PubMedGoogle ScholarCrossref
28.
Woerle  HJPimenta  WPMeyer  C  et al.  Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values.  Arch Intern Med 2004;164 (15) 1627- 1632PubMedGoogle ScholarCrossref
29.
Stratton  IMCull  CAAdler  AIMatthews  DRNeil  HAHolman  RR Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75).  Diabetologia 2006;49 (8) 1761- 1769PubMedGoogle ScholarCrossref
30.
Verdecchia  PReboldi  GAngeli  F  et al.  Adverse prognostic significance of new diabetes in treated hypertensive subjects.  Hypertension 2004;43 (5) 963- 969PubMedGoogle ScholarCrossref
31.
Barzilay  JIDavis  BRCutler  JA  et al. ALLHAT Collaborative Research Group, Fasting glucose levels and incident diabetes mellitus in older non-diabetic adults randomized to three different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  Arch Intern Med 2006;166 (20) 2191- 2201PubMedGoogle ScholarCrossref
32.
Bosch  JYusuf  SGerstein  HC  et al. DREAM Trial Investigators, Effect of ramipril on the incidence of diabetes.  N Engl J Med 2006;355 (15) 1551- 1562PubMedGoogle ScholarCrossref
Original Investigation
January 28, 2008

Clinical Outcomes by Race in Hypertensive Patients With and Without the Metabolic Syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Author Affiliations

Author Affiliations: Department of Medicine, General Clinical Research Center (Dr Wright), and Department of Family Medicine, Case Western Reserve University (Dr Harris-Haywood), Cleveland, Ohio; Coordinating Center for Clinical Trials, School of Public Health, The University of Texas Health Science Center at Houston (Ms Pressel, Mr Baimbridge, and Dr Davis); Kaiser Permanente of Georgia, Tucker (Dr Barzilay); Department of Medicine, MacNeal Center for Clinical Research, Berwyn, Illinois (Dr Bareis); Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston (Dr Basile); Section of Cardiology, Department of Internal Medicine, New York University School of Medicine, New York (Dr Black); Department of Nephrology, Marshfield Clinic, Marshfield, Wisconsin (Dr Dart); Pennington Biomedical Research Center, Baton Rouge, Louisiana (Dr Gupta); Hypertension-Endocrine Unit, Veterans Affairs Medical Center, Baltimore, Maryland (Dr Hamilton); Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland (Dr Einhorn); Division of Cardiovascular Medicine, University of Southern California Medical Center, Los Angeles (Dr Haywood); Department of Cardiology, Veterans Affairs Medical Center, Fargo, North Dakota (Dr Jafri); Tulane University Health Sciences Center, New Orleans, Louisiana (Ms Louis); Loyola University Medical Center, Maywood, Illinois (Dr Whelton); Cranford L. Scott, MD, Inc, Inglewood, California (Dr Scott); Department of Endocrinology, University of Arkansas for Medical Sciences, Little Rock (Dr Simmons); and University of Missouri Kansas City School of Medicine (Dr Stanford).

Arch Intern Med. 2008;168(2):207-217. doi:10.1001/archinternmed.2007.66
Abstract

Background  Antihypertensive drugs with favorable metabolic effects are advocated for first-line therapy in hypertensive patients with metabolic/cardiometabolic syndrome (MetS). We compared outcomes by race in hypertensive individuals with and without MetS treated with a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine besylate), an α-blocker (doxazosin mesylate), or an angiotensin-converting enzyme inhibitor (lisinopril).

Methods  A subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind hypertension treatment trial of 42 418 participants. We defined MetS as hypertension plus at least 2 of the following: fasting serum glucose level of at least 100 mg/dL, body mass index (calculated as weight in kilograms divided by height in meters squared) of at least 30, fasting triglyceride levels of at least 150 mg/dL, and high-density lipoprotein cholesterol levels of less than 40 mg/dL in men or less than 50 mg/dL in women.

Results  Significantly higher rates of heart failure were consistent across all treatment comparisons in those with MetS. Relative risks (RRs) were 1.50 (95% confidence interval, 1.18-1.90), 1.49 (1.17-1.90), and 1.88 (1.42-2.47) in black participants and 1.25 (1.06-1.47), 1.20 (1.01-1.41), and 1.82 (1.51-2.19) in nonblack participants for amlodipine, lisinopril, and doxazosin comparisons with chlorthalidone, respectively. Higher rates for combined cardiovascular disease were observed with lisinopril-chlorthalidone (RRs, 1.24 [1.09-1.40] and 1.10 [1.02-1.19], respectively) and doxazosin-chlorthalidone comparisons (RRs, 1.37 [1.19-1.58] and 1.18 [1.08-1.30], respectively) in black and nonblack participants with MetS. Higher rates of stroke were seen in black participants only (RR, 1.37 [1.07-1.76] for the lisinopril-chlorthalidone comparison, and RR, 1.49 [1.09-2.03] for the doxazosin-chlorthalidone comparison). Black patients with MetS also had higher rates of end-stage renal disease (RR, 1.70 [1.13-2.55]) with lisinopril compared with chlorthalidone.

Conclusions  The ALLHAT findings fail to support the preference for calcium channel blockers, α-blockers, or angiotensin-converting enzyme inhibitors compared with thiazide-type diuretics in patients with the MetS, despite their more favorable metabolic profiles. This was particularly true for black participants.

Trial Registration  clinicaltrials.gov Identifier: NCT00000542

×